James D. Campbell, MD, MS

Testing the safety, tolerability, and efficacy of important vaccines. One of the main themes of Dr. Campbell’s career is the careful clinical evaluation of vaccines in all phases of development.

• Campbell JD, Donegan S, Long (Clement) K, Chrisley L, Wasserman SS, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin. 2007 Sep-Oct;3(5):205-11.
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and imunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006 March 30;345: 1343-51.
• Campbell JD, Edelman R, King JC, Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis. 2002;186(12):1848-51.

Testing the safety, tolerability, and efficacy of HIV pre-exposure prophylaxis and evaluating home-based AIDS care. While living in Kampala, Uganda and working for the Centers for Disease Control and Prevention, Dr. Campbell evaluated a home-based AIDS care program and the use of antiretrovirals in preventing HIV transmission to the negative partners in heterosexual discordant couples. As a result of the latter work, tenofovir/emtricitabine was approved by the FDA for HIV prophylaxis.

• Haberer JE, Baeten JM, Campbell JD, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware N, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR. Adherence to antiretroviral prophylaxis for HIV prevention: A substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLOS Med. 2013 Sept 10.
• Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, Odongo G, Wetaka M, Mermin J, Tappero JW. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204-11.
• Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, and Celum C for the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.

Investigating the epidemiology of vaccine-preventable diseases. Dr. Campbell has worked in Mali, Uganda, and Ethiopia on vaccine-preventable disease epidemiology. The work in Mali led to the introduction of Hib vaccine there and the work in Ethiopia aims to assist the Ministry of Health in providing universal childhood vaccination coverage.

• Sow SO, Diallo S, Campbell JD, Tapia M, Keita T, Keita MM, Murray P, Kotloff KL, Levine MM. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: Impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J. 2005 June;24(6):533-7.
• Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, Diallo S, Hormazabal JC, Murray P, Levine MM. Invasive pneumococcal infections among hospitalized children in Bamako, Mali. Pediatr Infect Dis J. 2004 July;23 (7):642-9.

Dr. Campbell’s research interests include clinical trials of vaccines in all age groups, epidemiology of vaccine-preventable diseases, and HIV prevention. He has performed trials of vaccines against many organisms, including Neisseria meningitidis, Bacillus anthracis, seasonal influenza, pandemic influenza, and smallpox. Dr. Campbell has overseen trials for innovative vaccine administration techniques and coordinated vaccine trials of childhood immunizations at three pediatric clinic vaccine sites in Maryland.

He helped establish and oversee a microbiology laboratory at the pediatric hospital in Bamako, Mali where they investigated the causes of invasive bacterial infections, particularly Streptococcus pneumoniae and Haemophilus influenzae type b. From 2007 to 2012, he was a medical officer/epidemiologist with CDC’s Division of HIV/AIDS Prevention and the in-country Associate Director for Science in Kampala, Uganda. Dr. Campbell's work in Uganda included HIV prevention trials and research on Nodding Syndrome and other outbreaks.

Dr. Campbell sees patients and cares for children on the Pediatric Infectious Diseases Service at the University of Maryland Hospital for Children. This service includes both inpatient and outpatient referrals.

2021: Pediatrician of the Year, Maryland State Chapter of the American Academy of Pediatrics

2015, 2017, 2020, 2021: Baltimore Magazine’s Best Doctors: Pediatric Infectious Diseases

2012: Appreciation Award, The AIDS Support Organization (TASO)

2011: U.S. Embassy Uganda, Franklin Award for participation in identifying an outbreak of Yellow Fever in the north of Uganda

2009: U.S. Embassy Uganda, Meritorious Service Award for leadership in healthcare research in Uganda

2004: America’s Top Pediatricians Listing, Consumers’ Research Council of America

2004: Nomination, Maryland Immunization Excellence Award, Maryland Partnership for Prevention

1999: Alexander J. Schaffer Teaching Award for Outstanding Contributions to Housestaff Education, University of Maryland Medical Center

1998: Navy Commendation Medal

1997/1998: Outstanding Pediatric Teacher, National Naval Medical Center and Walter Reed Army Medical Center

1994: Outstanding Pediatric Teacher, Uniformed Services University of the Health Sciences

2012-present   James D. Campbell (Investigator, 5%) PI MM Levine

                        “Assesment of the Effectiveness of Infant Immunization Services in Ethiopia”

                                    Sponsor: John Snow International

                                    Funder: The Bill and Melinda Gates Foundation (OPP1017350)                             

                                    Total direct costs: $940,520

                                    Role: inform an Ethiopian Federal Ministry of Health (FMPH) evidence-based decision on nationwide universal child immunization; supervised the serosurvey while living in Ethoipia for 1 month in 2013 and in 2016

2013-present  James D. Campbell (Co-Principal Investigator, 20%) PI K Kotloff

                                    “Vaccine and Treatment Evaluation Units (VTEU-Clinical testing of vaccines and related products in human subjects.)  Award HHSN272201300022I (9/16/2013- 9/15/2023).

                                      Sponsor: National Institutes of Health, NIAID. (peer reviewed)

                                    Annual direct costs: IDIQ- minimum $10,000; max $95,170,200.

                                    Role: major role as an investigator and manager, includes acting as PI for multiple vaccine trials including DMID 17-0093, a Phase II study of anthrax vaccine with CPG7909 adjuvant

2018-present   James D. Campbell (PI, 5%)

                                    “Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers” (MET42                                   BB-IND #: 14171)

                                    Sponsor: Sanofi

                                    Total estimated direct costs: $172,644.03

                                    Role: As PI, I oversee the work performed at The Pediatric Center site in Frederick, Maryland where infants are enrolled.

2018-present   James D. Campbell (PI, 5%)

                                    “Double-Blind, Randomized, Placebo-Controlled, Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age” (V160-002)

                                    Sponsor: Merck

                                    Total estimated direct costs: $210,719.18

                                    Role: As PI, I oversee the work performed at The Pediatric Center site in Frederick, Maryland, the Pediatrics at Midtown site in Baltimore, and the site at the Center for Vaccine Development in Baltimore, where participants will be enrolled.

2018-present   James D. Campbell (PI, 5%)

                                    “A Phase IIIB, Randomized, Observer-Blind, Placebo-Controlled Multicenter Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-Valent Pneumococcal Vaccine When Administered Concomitantly with Routine Vaccines to Healthy Infants” (V72_57)

                                    Sponsor: GSK Biologicals

                                    Total estimated direct costs: $191,842.31

                                    Role: As PI, I will oversee the work performed at the Pediatrics at Midtown site in Baltimore, where infants will be enrolled.

2019-present   James D. Campbell (PI, 5%)

                                    “A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants.” GSK Protocol number 204894 (RSV PED-011)

                                    Sponsor: GSK Biologicals

                                    Total estimated direct costs: $68,855.38

                                    Role: As PI, I will oversee the work performed at the Pediatrics at Midtown site in Baltimore, where infants will be enrolled.

2020-present   James D. Campbell (PI, 5%)

                                    “A phase 3 randomized, double blind trial to evaluate the safety and immunogenicity of a 20 valent pneumococcal conjugate vaccine in healthy infants. Pfizer B7471011

                                    Sponsor: Pfizer

                                    Total estimated direct costs: $TBD

                                    Role: As PI, I will oversee the work performed at the Pediatrics at Midtown site in Baltimore and The Pediatric Center in Frederick, where infants will be enrolled.

2020-present   James D. Campbell (co-Director, 5%)

                                    “Collaborative Influenza Vaccine Innovative Centers (CIVICs)”    

                                    Sponsor: DMID/NIAID/NIH, Award 75N93019C00055

                                    Total estimated direct costs: $2,958,965 (core only; additional funds for each project up to $200 million)

                                    Dates: 09/16/2019 – 06/15/2026

                                    Role: As co-director, I help the director to oversee the work performed in this award, primarily in the role of testing influenza vaccines in pregnant women and children (eg, I am coordinating and site PI for a study of FluGen’s Phase II intranasal influenza vaccine in children).